Bioduro And Roche Expand Strategic Collaboration To Provide Drug Discovery Services

< BACK TO RESEARCH starstarstarstarstar   Science - Research Press Release
7th April 2009, 11:17am - Views: 970

Science Research BioDuro 1 image

BioDuro and Roche Expand Strategic Collaboration to Provide Drug Discovery Services

BEIJING, Apr. 7 /PRNewswire-AsiaNet/ --

    BioDuro announced today that they have entered into a strategic partnership with Roche to

support discovery phase research efforts at Roche's global research sites. BioDuro will provide

research services in the areas of

discovery chemistry and biology, which can help to shorten (internal) drug

discovery timelines. This agreement is an expansion of an existing relationship.

    Roche has many years of experience in partnering with external companies

to complement its internal drug discovery expertise with external services

and innovation. After extensive evaluation of many companies, Roche selected

BioDuro as a strategic partner for this effort.

    "Presently, there is intense competition within the CRO industry for

outsourcing and drug discovery services, and the expectation is that they

will deliver problem solving skills and innovation in both chemistry and

biology," commented Robert Goodnow, Ph.D., Roche's Global Head of Medicinal

Chemistry Outsourcing. "We selected BioDuro due to their demonstrated

excellent performance in synthetic chemistry and ability to deliver

integrated medicinal chemistry services."

    "BioDuro is pleased to build upon this existing collaboration and work

closely with the experienced team at Roche to aid in the development of novel

therapeutics. We care deeply about working on projects that will impact the

quality of life worldwide and working with Roche ensures this outcome. Our

partnership demonstrates the strength of our innovative, fully integrated R&D

service platform, and is a true testament to the caliber of scientists that

have joined our team," commented John Oyler, Chief Executive Officer and

co-founder of BioDuro LLC.

    About Roche

    Headquartered in Basel, Switzerland, Roche is one of the world's

leading research-focused healthcare groups in the fields of pharmaceuticals

and diagnostics. As the world's biggest biotech company and an innovator of

products and services for the early detection, prevention, diagnosis and

treatment of diseases, the Group contributes on a broad range of fronts to

improving people's health and quality of life. Roche is the world leader in

in-vitro diagnostics and drugs for cancer and transplantation, and is a

market leader in virology. It is also active in other major therapeutic areas

such as autoimmune diseases, inflammatory and metabolic disorders and

diseases of the central nervous system. In 2008, sales by the Pharmaceuticals

Science Research BioDuro 2 image

Division totalled 36.0 billion Swiss francs ($33.3B US), and the Diagnostics

Division posted sales of 9.7 billion francs ($9.0B US). Roche has R&D

agreements and strategic alliances with numerous partners, including majority

ownership interests in Genentech and Chugai, and invested nearly 9 billion

Swiss francs ($8.3B US) in R&D in 2008. Worldwide, the Group employs about

80,000 people. Additional information is available on the Internet at

    About BioDuro

    BioDuro is a US-based, fully-integrated, end-to-end, life

science, research services company with a team of 580 in Beijing, China.

BioDuro combines western pharmaceutical company quality and professionalism,

with entrepreneurial, innovative biotech research culture, to leverage its

talented, hard-working scientists. BioDuro's clients are over 40

pharmaceutical and biotechnology companies, including 10 of the top-12.

BioDuro's services span the entire range of drug discovery and development,

from discovery chemistry, discovery biology, early ADMET, DMPK, through

pharmacology and drug safety evaluation.


    CONTACT: Sharon Valdettaro, Roche Pharma Partnering, 


   , or 

             Roche Public Affairs, 

             Darien E. Wilson, 


   , both of Roche; or 

             Ryan Brady, Business Development, 


   , or 


             Ling Zhang, Public and Governmental Relations, 


   , both of BioDuro

To view this and other AsiaNet releases please visit

news articles logo NEWS ARTICLES
Contact News Articles |Remove this article